The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Myasthenia Gravis Drugs-Global Market Insights and Sales Trends 2025

Myasthenia Gravis Drugs-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1812260

No of Pages : 113

Ask Your Query
Synopsis
The global Myasthenia Gravis Drugs market size is expected to reach US$ 2404.4 million by 2029, growing at a CAGR of 7.6% from 2023 to 2029. The market is mainly driven by the significant applications of Myasthenia Gravis Drugs in various end use industries. The expanding demands from the Hospitals and Clinics, are propelling Myasthenia Gravis Drugs market. Anticholinesterases, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunosuppressants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Myasthenia Gravis Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Myasthenia Gravis Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Myasthenia Gravis Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Myasthenia Gravis Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Myasthenia Gravis Drugs covered in this report include Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Takeda, Novartis, Bausch Health, Alexion Pharmaceuticals and Catalyst Pharmaceuticals, etc.
The global Myasthenia Gravis Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Flamel Technologies
F. Hoffmann-La Roche
Grifols
Pfizer
Takeda
Novartis
Bausch Health
Alexion Pharmaceuticals
Catalyst Pharmaceuticals
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Global Myasthenia Gravis Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Myasthenia Gravis Drugs market, Segment by Type:
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins
Global Myasthenia Gravis Drugs market, by Application
Hospitals
Clinics
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Myasthenia Gravis Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Myasthenia Gravis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Myasthenia Gravis Drugs Market Overview
1.1 Myasthenia Gravis Drugs Product Overview
1.2 Myasthenia Gravis Drugs Market Segment by Type
1.2.1 Anticholinesterases
1.2.2 Immunosuppressants
1.2.3 Intravenous Immune Globulins
1.3 Global Myasthenia Gravis Drugs Market Size by Type
1.3.1 Global Myasthenia Gravis Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Myasthenia Gravis Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Myasthenia Gravis Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2023)
2 Global Myasthenia Gravis Drugs Market Competition by Company
2.1 Global Top Players by Myasthenia Gravis Drugs Sales (2018-2023)
2.2 Global Top Players by Myasthenia Gravis Drugs Revenue (2018-2023)
2.3 Global Top Players by Myasthenia Gravis Drugs Price (2018-2023)
2.4 Global Top Manufacturers Myasthenia Gravis Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Myasthenia Gravis Drugs Market Competitive Situation and Trends
2.5.1 Myasthenia Gravis Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Myasthenia Gravis Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
2.8 Key Manufacturers Myasthenia Gravis Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Myasthenia Gravis Drugs Status and Outlook by Region
3.1 Global Myasthenia Gravis Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Myasthenia Gravis Drugs Historic Market Size by Region
3.2.1 Global Myasthenia Gravis Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Myasthenia Gravis Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Myasthenia Gravis Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Myasthenia Gravis Drugs Forecasted Market Size by Region
3.3.1 Global Myasthenia Gravis Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Myasthenia Gravis Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Myasthenia Gravis Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Myasthenia Gravis Drugs by Application
4.1 Myasthenia Gravis Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.2 Global Myasthenia Gravis Drugs Market Size by Application
4.2.1 Global Myasthenia Gravis Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Myasthenia Gravis Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Myasthenia Gravis Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2023)
5 North America Myasthenia Gravis Drugs by Country
5.1 North America Myasthenia Gravis Drugs Historic Market Size by Country
5.1.1 North America Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Myasthenia Gravis Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Myasthenia Gravis Drugs Sales in Value by Country (2018-2023)
5.2 North America Myasthenia Gravis Drugs Forecasted Market Size by Country
5.2.1 North America Myasthenia Gravis Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Myasthenia Gravis Drugs Sales in Value by Country (2024-2029)
6 Europe Myasthenia Gravis Drugs by Country
6.1 Europe Myasthenia Gravis Drugs Historic Market Size by Country
6.1.1 Europe Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Myasthenia Gravis Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Myasthenia Gravis Drugs Sales in Value by Country (2018-2023)
6.2 Europe Myasthenia Gravis Drugs Forecasted Market Size by Country
6.2.1 Europe Myasthenia Gravis Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Myasthenia Gravis Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Myasthenia Gravis Drugs by Region
7.1 Asia-Pacific Myasthenia Gravis Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Myasthenia Gravis Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Myasthenia Gravis Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Myasthenia Gravis Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Myasthenia Gravis Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Myasthenia Gravis Drugs Sales in Value by Region (2024-2029)
8 Latin America Myasthenia Gravis Drugs by Country
8.1 Latin America Myasthenia Gravis Drugs Historic Market Size by Country
8.1.1 Latin America Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Myasthenia Gravis Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Myasthenia Gravis Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Myasthenia Gravis Drugs Forecasted Market Size by Country
8.2.1 Latin America Myasthenia Gravis Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Myasthenia Gravis Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Myasthenia Gravis Drugs by Country
9.1 Middle East and Africa Myasthenia Gravis Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Myasthenia Gravis Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Myasthenia Gravis Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Myasthenia Gravis Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Myasthenia Gravis Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Myasthenia Gravis Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Flamel Technologies
10.1.1 Flamel Technologies Company Information
10.1.2 Flamel Technologies Introduction and Business Overview
10.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
10.1.5 Flamel Technologies Recent Development
10.2 F. Hoffmann-La Roche
10.2.1 F. Hoffmann-La Roche Company Information
10.2.2 F. Hoffmann-La Roche Introduction and Business Overview
10.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products Offered
10.2.5 F. Hoffmann-La Roche Recent Development
10.3 Grifols
10.3.1 Grifols Company Information
10.3.2 Grifols Introduction and Business Overview
10.3.3 Grifols Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Grifols Myasthenia Gravis Drugs Products Offered
10.3.5 Grifols Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Information
10.4.2 Pfizer Introduction and Business Overview
10.4.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Pfizer Myasthenia Gravis Drugs Products Offered
10.4.5 Pfizer Recent Development
10.5 Takeda
10.5.1 Takeda Company Information
10.5.2 Takeda Introduction and Business Overview
10.5.3 Takeda Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Takeda Myasthenia Gravis Drugs Products Offered
10.5.5 Takeda Recent Development
10.6 Novartis
10.6.1 Novartis Company Information
10.6.2 Novartis Introduction and Business Overview
10.6.3 Novartis Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Novartis Myasthenia Gravis Drugs Products Offered
10.6.5 Novartis Recent Development
10.7 Bausch Health
10.7.1 Bausch Health Company Information
10.7.2 Bausch Health Introduction and Business Overview
10.7.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Bausch Health Myasthenia Gravis Drugs Products Offered
10.7.5 Bausch Health Recent Development
10.8 Alexion Pharmaceuticals
10.8.1 Alexion Pharmaceuticals Company Information
10.8.2 Alexion Pharmaceuticals Introduction and Business Overview
10.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products Offered
10.8.5 Alexion Pharmaceuticals Recent Development
10.9 Catalyst Pharmaceuticals
10.9.1 Catalyst Pharmaceuticals Company Information
10.9.2 Catalyst Pharmaceuticals Introduction and Business Overview
10.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products Offered
10.9.5 Catalyst Pharmaceuticals Recent Development
10.10 CSL
10.10.1 CSL Company Information
10.10.2 CSL Introduction and Business Overview
10.10.3 CSL Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 CSL Myasthenia Gravis Drugs Products Offered
10.10.5 CSL Recent Development
10.11 Curavac
10.11.1 Curavac Company Information
10.11.2 Curavac Introduction and Business Overview
10.11.3 Curavac Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Curavac Myasthenia Gravis Drugs Products Offered
10.11.5 Curavac Recent Development
10.12 Cytokinetics
10.12.1 Cytokinetics Company Information
10.12.2 Cytokinetics Introduction and Business Overview
10.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Cytokinetics Myasthenia Gravis Drugs Products Offered
10.12.5 Cytokinetics Recent Development
10.13 Galencia
10.13.1 Galencia Company Information
10.13.2 Galencia Introduction and Business Overview
10.13.3 Galencia Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Galencia Myasthenia Gravis Drugs Products Offered
10.13.5 Galencia Recent Development
10.14 GlaxoSmithKline
10.14.1 GlaxoSmithKline Company Information
10.14.2 GlaxoSmithKline Introduction and Business Overview
10.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 GlaxoSmithKline Myasthenia Gravis Drugs Products Offered
10.14.5 GlaxoSmithKline Recent Development
10.15 Lupin Pharmaceuticals
10.15.1 Lupin Pharmaceuticals Company Information
10.15.2 Lupin Pharmaceuticals Introduction and Business Overview
10.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Products Offered
10.15.5 Lupin Pharmaceuticals Recent Development
10.16 Mitsubishi Tanabe Pharma
10.16.1 Mitsubishi Tanabe Pharma Company Information
10.16.2 Mitsubishi Tanabe Pharma Introduction and Business Overview
10.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Products Offered
10.16.5 Mitsubishi Tanabe Pharma Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Myasthenia Gravis Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Myasthenia Gravis Drugs Industrial Chain Analysis
11.4 Myasthenia Gravis Drugs Market Dynamics
11.4.1 Myasthenia Gravis Drugs Industry Trends
11.4.2 Myasthenia Gravis Drugs Market Drivers
11.4.3 Myasthenia Gravis Drugs Market Challenges
11.4.4 Myasthenia Gravis Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Myasthenia Gravis Drugs Distributors
12.3 Myasthenia Gravis Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock